OR WAIT 15 SECS
A development and manufacturing partnership with Thermo will allow Civica to expand its internal pipeline of medications for use in emergency and critical care in the United States, further preventing the risk of drug shortages.
Civica Rx, a non-profit, non-stock corporation dedicated to maintaining the supply of essential generic medications, announced on Jan. 16, 2020 that it signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture Civica-owned Abbreviated New Drug Applications (ANDAs).
The seven-year partnership will target nine drugs that have been in short supply or where there is a risk of shortage because there are too few manufacturers, a Civica press release said. If successful, Civica can expand its internal pipeline of medications for use in emergency and critical care in the United States, further preventing the risk of drug shortages.
“We are thrilled to enter into a partnership with a world class organization that is dedicated to helping Civica serve patients,” said Martin VanTrieste, Civica’s president and CEO, in the press release. “The Thermo Fisher team is known for top manufacturing talent, supply reliability, product quality, and innovation. We look forward to working with them to develop and produce Civica medicines.”
“We thank Civica for their confidence in our team and capabilities and welcome this opportunity to work with them to help mitigate the risk of drug shortages in the US,” added Mike Shafer, president of Thermo Fisher’s Pharma Services business, in the press release. “Together we will be able to deliver medicines to the market sooner to the patients who are waiting.”